coxsackieviru
import
coxsacki
b
viru
genu
enterovirus
within
famili
picornavirida
also
isol
hand
foot
mouth
diseas
hfmd
patient
often
associ
neurolog
manifest
studi
found
coxsackieviru
replicon
rna
could
encapsid
capsid
assembl
infecti
pseudoviru
util
singl
round
infect
system
develop
neutral
antibodi
quantif
assay
pseudoviru
neutral
assay
show
superior
biosafeti
sensibl
quantit
effici
high
throughput
would
facilit
epidemiolog
studi
vaccin
develop
coxsackieviru
one
promin
serotyp
coxsacki
b
virus
belong
genu
enteroviru
within
famili
picornavirida
infect
human
often
associ
seriou
neurolog
symptom
like
asept
mening
although
less
common
neurolog
symptom
cardiomyopathi
diabet
also
report
infect
case
grumbach
et
al
marier
et
al
mening
case
caus
report
mani
countri
includ
unit
state
kopecka
et
al
tavakoli
et
al
belgium
thoelen
et
al
greec
papa
et
al
franc
antona
et
al
spain
trallero
et
al
brazil
do
santo
et
al
korea
baek
et
al
lee
et
al
india
kumar
et
al
among
other
china
sporad
infect
case
frequent
outbreak
also
report
chen
et
al
yen
et
al
although
enteroviru
coxsackieviru
first
recogn
major
pathogen
respons
hand
foot
mouth
diseas
hfmd
outbreak
sever
enterovirus
also
isol
patient
sinc
hfmd
list
notifi
diseas
nation
surveil
system
mani
countri
coxsackieviru
han
et
al
hu
et
al
coxsackieviru
bian
et
al
fujimoto
et
al
osterback
et
al
coxsackieviru
lu
et
al
coxsackieviru
gao
et
al
wu
et
al
fujimoto
et
al
wang
et
al
wu
et
al
infect
neurolog
manifest
recogn
seriou
threat
hfmd
control
effort
underway
develop
prophylact
vaccin
klein
chong
shown
mani
time
detect
method
use
monitor
neutral
antibodi
ntab
titer
predict
vivo
protect
efficaci
vaccin
plotkin
jin
et
al
data
acquir
via
detect
method
help
gener
predict
insight
epidemiolog
studi
eg
histor
infect
popul
immun
gao
et
al
ji
et
al
current
convent
practic
antienteroviru
ntab
titer
measur
employ
microtit
plate
neutral
assay
base
inhibitori
effect
ntab
cytopath
effect
cpe
cell
chonmaitre
et
al
although
method
use
long
time
biosafeti
concern
use
assay
major
shortcom
semiquantit
laborintens
timeconsum
requir
least
day
result
obtain
weak
highlight
need
develop
superior
altern
method
quantif
ntab
titer
genet
modifi
pseudovirus
express
luciferas
report
use
measur
ntab
pseudovirusbas
neutral
assay
offer
superior
biosafeti
improv
sensit
perform
assay
wild
type
virus
thu
surpris
pseudoviru
assay
increasingli
popular
use
measur
ntab
titer
human
immunodefici
viru
hiv
montefiori
et
al
influenza
viru
tsai
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
li
et
al
http
sui
et
al
past
research
group
focus
hfmd
associ
enterovirus
date
develop
infecti
pseudovirus
caus
cpe
effect
cell
establish
safe
effici
pseudovirusbas
ntab
detect
method
enteroviru
wu
et
al
coxsackieviru
coxsackieviru
success
establish
robust
pseudoviru
infect
system
subsequ
develop
pseudovirusbas
neutral
assay
measur
ntab
titer
direct
comparison
tradit
cpebas
microtit
plate
neutral
assay
new
pseudovirusbas
assay
reveal
new
method
superior
term
biosafeti
detect
limit
quantit
perform
new
method
thu
view
desir
replac
previouslystandard
cpe
assay
quantif
ntab
titer
human
embryon
kidney
hek
cell
maintain
dulbecco
modifi
essenti
media
dmem
thermo
contain
fetal
bovin
serum
gibco
penicillinstreptomycin
thermo
co
atmospher
human
rhabdomyosarcoma
rd
cell
vero
cell
hela
cell
maintain
minimum
essenti
media
mem
thermo
contain
fetal
bovin
serum
penicillin
streptomycin
co
atmospher
strain
genbank
access
isol
threeyearold
patient
diagnos
herpangina
pizhou
citi
china
follow
antisera
gener
via
immun
mice
mous
serum
immunogen
inactiv
viru
strain
mous
serum
immunogen
inactiv
viru
genbank
access
number
subtyp
mous
anticoxsackieviru
serum
immunogen
inactiv
strain
genbank
access
number
mous
antihepat
e
viru
hev
immunogen
hev
vaccin
hecolin
produc
xiamen
innovax
biotech
co
ltd
mous
serum
immunogen
strain
kindli
provid
dr
ningshao
xia
genbank
access
number
mous
immunogen
inactiv
strain
plasma
sampl
collect
healthi
adult
donor
blood
center
establish
hualan
biolog
engin
inc
approv
local
ethic
review
board
written
inform
consent
obtain
particip
hela
cell
infect
moi
multipl
infect
total
rna
isol
trizol
reagent
cell
round
revers
transcrib
use
superscript
iii
rt
thermo
full
length
cdna
amplifi
use
phusion
highfidel
dna
polymeras
new
england
biolab
two
primer
amplif
product
insert
vector
psva
use
infus
hd
clone
kit
clontech
design
promot
sequenc
ad
end
cdna
prepar
viral
genom
sequenc
full
length
cdna
verifi
sanger
sequenc
infecti
wild
type
viru
rescu
cotransfect
hela
cell
plasmid
express
polymeras
polymers
briefli
equal
amount
two
plasmid
cotransfect
use
jetprim
polyplu
hela
cell
grown
confluenc
supernat
sampl
contain
infecti
viru
collect
cotransfect
cell
show
cpe
debri
clarif
centrifug
store
aliquot
capsid
gene
amplifi
egfp
gene
insert
upstream
capsid
gene
proteas
self
cleavag
site
aittl
egfp
report
use
monitor
transfect
effici
express
level
four
viral
structur
gene
pseudoviru
produc
cotransfect
replicon
plasmid
capsid
express
capsid
express
capsid
express
capsid
express
polymeras
briefli
three
plasmid
mix
ratio
revers
transfect
cell
confluenc
jetprim
polyplu
h
post
capsid
transfect
virion
harvest
supernat
cell
lysat
follow
freezethaw
cycl
debri
clarif
centrifug
sampl
store
aliquot
quantif
nanci
luc
pseudoviru
qpcr
pseudoviru
supernat
initi
treat
dnase
new
england
biolab
remov
plasmid
residu
contamin
viral
rna
extract
qiaamp
viral
rna
mini
kit
qiagen
cdna
synthes
primescript
rt
reagent
kit
takara
genom
copi
equival
quantifi
qpcr
use
primer
target
firefli
luciferas
report
gene
sybr
premix
ex
taq
ii
perfect
real
time
takara
qlucf
qlucr
plasma
sampl
heattreat
min
inactiv
complement
plasma
sampl
twofold
serial
dilut
rang
mix
equal
volum
dilut
pseudoviru
incub
h
rd
singl
cell
suspens
ml
ad
incub
co
incub
h
next
incub
medium
discard
cell
lyze
passiv
lysi
buffer
promega
two
freezethaw
cycl
luciferas
activ
report
rel
light
unit
rlu
measur
accord
user
manual
luciferas
assay
system
berthold
viral
inhibit
ratio
calcul
rlu
serumplasma
rlu
background
rlu
viruscontrol
rlu
background
titer
ntab
defin
reciproc
dilut
pseudoviru
neutral
previous
describ
wu
et
al
twofold
serial
dilut
sera
start
mix
equal
volum
viru
work
solut
contain
tissu
cultur
infect
dose
strain
h
microtit
plate
vero
cell
ml
ad
incub
day
sera
test
duplic
neutral
titer
defin
reciproc
highest
dilut
well
show
complet
cpe
inhibit
sampl
titer
consid
posit
otherwis
neg
experiment
data
collect
minimum
duplic
sampl
data
report
mean
standard
deviat
replicon
capsid
express
describ
previous
briefli
replicon
produc
replac
region
firefli
luciferas
report
gene
full
length
genom
promot
place
end
transcript
initi
capsid
express
use
express
capsid
protein
tran
egfp
gene
insert
upstream
separ
self
cleavag
site
aittl
capsid
express
construct
accordingli
b
transencapsid
compat
subgenom
replicon
capsid
express
subgenom
replicon
capsid
express
polymeras
cotransfect
cell
supernat
sampl
collect
h
post
transfect
hela
cell
seed
plate
incub
supernat
sampl
luciferas
activ
measur
h
post
infect
c
infect
pseudoviru
could
neutral
mous
serum
dilut
pseudovirus
mix
equal
volum
serial
dilut
mous
serum
duplic
respect
incub
h
hela
cell
ml
ad
incub
co
incub
luciferas
activ
measur
h
post
infect
nonlinear
regress
perform
graphpad
prism
specif
pseudoviru
dilut
pseudovirus
mix
equal
volum
dilut
mous
hev
serum
sampl
duplic
respect
incub
h
hela
cell
ml
ad
incub
co
incub
luciferas
activ
measur
h
post
infect
sd
nonlinear
regress
spearman
correl
analysi
blandaltman
method
comparison
analysi
perform
graphpad
prism
softwar
previous
report
pseudoviru
infect
system
structur
gene
replac
firefli
luciferas
report
along
proteas
cleavag
site
promot
place
upstream
initi
transcript
subgenom
replicon
fig
replicon
rna
could
encapsid
capsid
protein
respect
capsid
express
provid
first
attempt
produc
pseudoviru
replicon
rna
capsid
howev
pseudoviru
encapsid
success
use
vitro
transcrib
replicon
rna
next
tri
cotransfect
replicon
capsid
express
polymeras
vivo
transcrib
replicon
rna
also
fail
produc
pseudoviru
luciferas
report
data
shown
inspir
find
could
pseudotyp
replicon
rna
capsid
found
replicon
rna
instead
replicon
rna
could
effici
encapsid
capsid
produc
infecti
pseudoviru
fig
pseudoviru
design
capsid
compos
capsid
protein
antigen
wild
type
viru
highli
preserv
thu
infect
hela
cell
permiss
cell
line
could
inhibit
mous
serum
dose
depend
manner
fig
specif
confirm
panel
mous
antisera
enterovirus
well
hepat
e
viru
hev
fig
taken
togeth
result
show
could
effici
pseudotyp
replicon
rna
capsid
pseudoviru
could
use
surrog
wild
type
viru
sinc
could
elicit
singl
round
infect
could
excel
tool
studi
viral
entri
process
well
molecular
interact
viral
capsid
viral
receptor
besid
could
also
provid
superior
way
ntab
detect
next
aim
develop
vitro
neutral
assay
base
first
compar
rel
infect
three
common
cell
line
report
permiss
infect
chose
rd
cell
line
assay
develop
fig
cell
number
optim
maxim
readout
rel
light
unit
rlu
fig
singl
round
infect
system
show
superior
quantit
measur
infect
event
term
good
linear
correspond
rlu
amount
viru
input
broad
rang
fig
pilot
studi
three
human
plasma
sampl
healthi
adult
donor
analyz
use
pseudovirusbas
neutral
assay
ntab
could
detect
sampl
variou
level
fig
semiquantit
cpe
assay
tradit
consid
golden
method
measur
ntab
enterovirus
next
perform
comparison
studi
quantifi
ntab
human
plasma
sampl
pseudoviru
assay
cpe
assay
ntab
titer
cpe
assay
defin
reciproc
highest
dilut
well
show
complet
inhibit
cpe
sampl
titer
consid
posit
otherwis
neg
pseudoviru
assay
titer
defin
reciproc
dilut
pseudoviru
neutral
could
interpol
neutral
curv
nonlinear
regress
analysi
graphpad
prism
titer
two
assay
statist
analyz
plasma
sampl
posit
cpe
assay
cpe
posit
sampl
also
posit
pseudoviru
assay
sensit
specif
well
ppv
npv
experiment
condit
respect
titer
plasma
sampl
use
comparison
analysi
spearman
correl
analysi
show
good
correl
result
two
assay
r
p
fig
blandaltman
method
comparison
analysi
show
two
method
highli
consist
averag
logarithm
differ
quantit
result
two
method
standard
deviat
fig
fail
initi
attempt
us
replicon
rnato
produc
pseudoviru
instabl
replicon
rna
pseudoviru
produc
cell
anticip
data
shown
howev
replicon
rna
compar
stabl
pseudoviru
product
phylogenet
studi
reveal
intraserotyp
recombin
clinic
isol
suggest
may
unstabl
genom
structur
et
al
oberst
et
al
possibl
genet
modif
genom
may
aggrav
put
instabl
pseudoviru
infect
system
repres
yet
anoth
success
applic
transencapsid
strategi
produc
infecti
pseudoviru
replicon
rna
could
encapsid
capsid
produc
infecti
pseudoviru
replicon
rna
could
encapsid
capsid
previous
report
replicon
rna
could
encapsid
capsid
produc
infecti
pseudoviru
replicon
rna
could
encapsid
capsid
pattern
compat
transencapsid
experi
suggest
similar
virion
assembl
mechan
may
share
howev
seem
like
transencapsid
mechan
adopt
distinct
adopt
notabl
coxsackieviru
cv
group
enterovirus
known
share
viral
receptor
human
scaveng
receptor
class
b
member
yamayoshi
et
al
similarli
group
b
enterovirus
share
receptor
coxsackievirusadenoviru
receptor
car
bergelson
et
al
tomko
et
al
light
relationship
would
intrigu
classifi
mani
enterovirus
accordingli
explor
like
major
determin
involv
enteroviru
assembl
anticip
replicon
rna
could
use
probe
analyz
assembl
compat
among
group
group
b
enterovirus
work
develop
sensit
ntab
quantif
assay
base
pseudoviru
found
ntab
posit
adult
high
compar
pseudoviru
assay
cpe
assay
refer
gold
standard
assay
detect
antienteroviru
ntab
although
improv
specif
need
futur
pseudoviru
base
assay
provid
superior
replac
ntab
detect
develop
antiserum
refer
standard
would
help
optim
pseudoviru
assay
proper
cutoff
valu
achiev
highest
youden
index
could
set
produc
best
balanc
overal
agreement
sensit
specif
respect
refer
cpe
assay
date
establish
pseudoviru
base
ntab
quantif
assay
follow
success
licensur
vaccin
china
chang
hfmd
pathogen
spectrum
notic
multival
vaccin
health
threaten
enterovirus
cocircul
hfmd
epidem
propos
ideal
hfmd
control
klein
chong
mao
et
al
challeng
mani
aspect
multival
vaccin
develop
eg
select
potenti
vaccin
strain
klein
chong
safe
conveni
robust
bioassay
well
anim
model
efficaci
evalu
necessarili
requir
aforement
pseudovirusbas
ntab
quantif
assay
hfmd
associ
enterovirus
could
use
evalu
vaccin
induc
humor
immun
respons
establish
refer
standard
like
antiserum
standard
measur
vaccineinduc
ntab
titer
also
import
part
bioassay
develop
cooper
et
al
liang
et
al
furthermor
new
infect
mous
model
success
establish
base
pseudoviru
also
show
impress
advantag
efficaci
evalu
vaccin
thu
introduct
enterovirus
pseudovirus
eg
mous
infect
model
would
also
greatli
facilit
develop
multival
vaccin
hfmd
